If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 9 of 9
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Objective
This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Protocol No
HOFFMANN-BO41932-TAPISTRY
A Phase 1, Dose-Finding Study of Debio 0123 as Monotherapy in Adult Patients with Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-Tumor Activity
Objective
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adults
Protocol No
DEBIOPHARM-DEBIO0123-102
Categories
A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin Versus No HIPEC At the Time of Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian
Objective
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal & FT
Protocol No
GOG-3068-HOTT-HIPEC
Categories
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Objective
To compare the non-inferiority of bilateral salpingectomy (BLS) with delayed oophorectomy to bilateral salpingo-oophorectomy (BSO) to reduce the risk of ovarian cancer among women with deleterious BRCA1 germline mutations.
Protocol No
NRG-CC008
Categories
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Subjects with KRAS G12C Mutant Advanced Solid Tumors
Objective
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
Categories
Cancer,
Kidney,
Other Skin,
Thoracic Cancers,
Sarcoma,
Gastrointestinal Cancers,
Cervix,
Prostate and Urologic Cancers,
Other Gynecologic,
Breast Cancers,
Ovary,
Gynecologic Cancers,
Head and Neck Cancers,
Early Phase/Multiple Disease Site Cancers,
Endocrine Cancers,
Melanoma, Skin,
Eye/Orbital Cancers,
Skin Cancers
REMASTer: REcurrent Brain Metastases After SRS Trial
Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer,
Endocrine Cancers,
Uterine,
Other Urologic,
Colorectal,
Cervix,
Lung,
Brain and Spine Cancers,
Prostate,
Stomach,
Skin Cancers,
Prostate and Urologic Cancers,
Other Respiratory,
Gastrointestinal Cancers,
Breast Cancers,
Head and Neck Cancers,
Esophagus,
Ovary,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Gynecologic Cancers,
Sarcoma,
Eye/Orbital Cancers
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Objective
Phase 1/2, Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Protocol No
TAKEDA-TAK-280-1501
A Phase 1 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
Objective
A Phase 1 Study of NM32-2668 in Patients with Selected Advanced Solid Tumors
Protocol No
NUMAB-NB-NM032-2668-101
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
Objective
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Protocol No
SWOG-S2012